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Background: Alpha-1 antitrypsin is the main inhibitor of neutrophil elastase in the lung. Although it is principally
synthesized by hepatocytes, alpha-1 antitrypsin is also secreted by bronchial epithelial cells. Gene mutations can
lead to alpha-1 antitrypsin deficiency, with the Z variant being the most clinically relevant due to its propensity to
polymerize. The ability of bronchial epithelial cells to produce Z-variant protein and its polymers is unknown.
We investigated the expression, accumulation, and secretion of Z-alpha-1 antitrypsin and its polymers in cultures of
transfected cells and in cells originating from alpha-1 antitrypsin-deficient patients.
Methods: Experiments using a conformation-specific antibody were carried out on M- and Z-variant–transfected 16HBE
cells and on bronchial biopsies and ex vivo bronchial epithelial cells from Z and M homozygous patients. In addition,
the effect of an inflammatory stimulus on Z-variant polymer formation, elicited by Oncostatin M, was investigated.
Comparisons of groups were performed using t-test or ANOVA. Non-normally distributed data were assessed by
Mann–Whitney U test or the Kruskal-Wallis test, where appropriate. A P value of < 0.05 was considered to be significant.
Results: Alpha-1 antitrypsin polymers were found at a higher concentration in the culture medium of ex vivo bronchial
epithelial cells from Z-variant homozygotes, compared with M-variant homozygotes (P < 0.01), and detected in the
bronchial epithelial cells and submucosa of patient biopsies. Oncostatin M significantly increased the expression of
alpha-1 antitrypsin mRNA and protein (P < 0.05), and the presence of Z-variant polymers in ex vivo cells (P < 0.01).
Conclusions: Polymers of Z-alpha-1 antitrypsin form in bronchial epithelial cells, suggesting that these cells may be
involved in the pathogenesis of lung emphysema and in bronchial epithelial cell dysfunction.
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Alpha-1 antitrypsin (AAT) is the main proteinase inhibi-
tor within the lung. It is produced primarily by hepato-
cytes from where it is secreted into the plasma. It then
diffuses into the lung where it acts as the main inhibitor
of neutrophil elastase [1,2]. It is also produced by bron-
chial epithelial cells (BECs), macrophages, and poly-
morphonuclear leukocytes and neutrophils [3-5].* Correspondence: laura.pini@unibs.it
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unless otherwise stated.Wild-type AAT protein is known as M-AAT [6], how-
ever, more than 100 variants have been described of
which the Z variant is the most clinically relevant. The Z
mutant of AAT has a point mutation, Glu342Lys, in the
hinge region of the molecule that renders it inactive and
prone to intermolecular linkage and loop-sheet polymeriza-
tion. Polymers of Z-AAT aggregate within the cells that
produce this form of the protein leading to reduced AAT
secretion.
The pathogenesis of emphysema in Z-AAT homozy-
gotes is complex, but two main mechanisms have been
reported. Firstly, severe deficiency of AAT within the al-
veoli allows uncontrolled proteolytic attack and tissue. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics
M-AAT (n = 7) Z-AAT (n = 7) P value
Gender
Male 6 4 -
Female 1 3 -
Age (yr) M ± SEM 64.2 ± 21 48 ± 6.70 0.4765
AAT (mg/dl) M ± SEM 130 ± 26 49.29 ± 14.18 0.0184
FEV1 (% predicted) M ± SEM 69.7 ± 28.1 77 ± 15.20 0.8231
Definition of abbreviations: AAT = alpha-1 antitrypsin; FEV1 = forced expiratory
volume in 1 second; M = mean; SEM = standard error of mean.
Pini et al. Respiratory Research 2014, 15:112 Page 2 of 10
http://respiratory-research.com/content/15/1/112destruction. This mechanism has formed the corner-
stone of the proteinase-antiproteinase hypothesis of tis-
sue damage [7-14]. Secondly, Z-AAT is approximately
five-fold less efficient at inhibiting neutrophil elastase
than normal M-AAT [15,16]. An additional mechanism
may be the pro-inflammatory effect of Z-AAT polymers
in the lungs: polymers can be detected in Z-AAT homo-
zygotes’ bronchoalveolar lavage fluid, they are chemotac-
tic to neutrophils in vivo [17,18], they co-localize with
neutrophils in the alveoli of Z-AAT patients, and they
are pro-inflammatory in cell and mouse models of dis-
ease [19]. These data raised the additional hypothesis
that Z-AAT undergoes a conformational transition to
polymers within the lungs and that this transforms AAT
into a local pro-inflammatory stimulus [17-20], which
provides an explanation for the excessive number of
neutrophils in the lungs of Z-AAT homozygotes and the
progression of disease, despite adequate AAT replace-
ment [19].
Mechanisms that drive formation of Z-AAT polymers
in the lung and their cellular origin are still unknown.
These polymers could be derived from circulating
monomeric plasma AAT, from polymorphonuclear neu-
trophils, or from local respiratory cells. It is known that
AAT can be synthesized and secreted by BECs, especially
during inflammation, but little is known about the
synthesis, accumulation, and secretion of Z-AAT or its
polymers by BECs. In addition, the hypothetical cyto-
toxic effect (either direct or in association with the neu-
trophils) of polymer accumulation in airway epithelial
cells has yet to be shown. To elucidate the source of Z-
AAT polymers in the lung and the role of BECs in the
pathogenesis of lung emphysema and airway dysfunction
in AAT-deficient patients, we have investigated the ex-
pression, accumulation, and secretion of Z-AAT protein
by BECs, with particular attention to the presence of
Z-AAT polymers. In addition, the effect of an inflamma-
tory stimulus on this process, provided by Oncostatin
M, was analyzed to provide further insights as to




Homozygous patients for Z-AAT and M-AAT (seven for
each genotype) with diagnosed emphysema were se-
lected at our Regional Reference Centre for AAT Defi-
ciency (Department of Internal Medicine, Brescia, Italy)
[21,22] following approval from ethics committees of
Spedali Civili of Brescia and having obtained informed
consent. At the time of inclusion, subjects were aged
18–70 years, non- or ex-smokers (>10 pack-years) for at
least 5 years, and in a stable condition (Table 1). The ex-
clusion criteria are detailed in the Additional file 1.A complete medical history was collected, with par-
ticular attention to previous smoking and pharmacologic
therapy. Plasma AAT levels were measured and the pa-
tient’s genotype determined by polymerase chain reac-
tion (PCR) with fluorescently labelled Taq-Man probes
(Vic or Fam labels) on a LightCycler480 (Roche Diag-
nostics Limited, Burgess Hill, UK). High-resolution com-
puted tomography was performed to detect the extent of
pulmonary emphysema. Arterial blood gas analysis and
pulmonary function tests, including spirometry, flow-
volume curve, lung volume measurements, and carbon
monoxide gas-transfer factor, were performed.Bronchoscopy
Bronchoscopy was performed according to standard pro-
cedures (please refer to Additional file 1). Two to four
biopsy specimens per patient were taken from the carina
of segmental bronchi using cup forceps. Biopsy speci-
mens were placed in Tris-buffered saline solution and
immediately processed for immunohistochemical experi-
ments. Tissues were fixed in 4% v/v paraformaldehyde,
embedded in paraffin, sectioned (2 μm), placed on glass
slides coated with poly-L-lysine (0.1% w/v), and baked
overnight at 37°C.
Epithelial brushings were obtained using a fiber-optic
bronchoscope in accordance with standard guidelines
[23]. BECs were obtained using a sterile single-sheathed
nylon cytology brush. On average, seven to eight con-
secutive brushings were sampled from the bronchial mu-
cosa of the second- and third-generation bronchi. Cells
were harvested into 5-ml sterile phosphate-buffered sa-
line after each brushing, and then recovered by centrifu-
gation [24].16HBE cell culture and transfections
The human BECs (16HBE) [25] were maintained in cul-
ture as described [26]. Complementary DNA for human
M and variant Z (G342L) AAT cloned into the mamma-
lian expression vector pcDNA3.1/Zeo (+) were transiently
transfected into cells using Lipofectamine™ 2000 (Invitro-
gen, Carlsbad, CA, USA), according to the manufacturer’s
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Immunohistochemistry of biopsy tissue
Tissue biopsy were obtained according to standard proce-
dures as detailed in the Additional file 1. To detect positive
staining of the epithelial layer, paraformaldehyde-fixed,
paraffin-embedded biopsy sections were incubated with the
ATZ11 antibody, which binds with high affinity to poly-
meric Z-AAT [27], or the isotype control mouse IgG (Vec-
tor Laboratories, Orton Southgate, Peterborough, UK).
Sections were developed with Fast Red salt and counter-
stained with Gill II hematoxylin. Two blinded observers per
patient group analyzed and quantified the tissue distribu-
tion of AAT. For further information, please refer to
Additional file 1.
Ex vivo cell cultures
Primary cultures of cells from bronchial epithelial cells
were established as described previously [24]. Minor
modifications are detailed in the Additional file 1.
Oncostatin M treatment
Cultures of untransfected 16HBE cells and ex vivo primary
cultures of human BECs were supplemented with 50 ng/ml
Oncostatin M (R&D Systems Inc., Minneapolis, MN, USA)
for 24 hours.
Western blots to assess AAT expression
Sodium dodecyl sulphate (SDS) or nondenaturing poly-
acrylamide gel electrophoresis (PAGE) followed by Western
blot analyses were carried out on transfected and nontrans-
fected 16HBE cells and ex vivo cultured BECs, using an
anti-AAT antibody that detect all conformations of AAT
(Total-AAT, DakoCytomation Ltd) or ATZ11 antibody.
Quantification of AAT expression
Reverse transcription real-time PCR (real-time-PCR)
and enzyme-linked immunosorbent assay (ELISA) ex-
periments were used to detect respectively the expres-
sion levels of AAT mRNA and the protein levels of
monomeric and polymeric AAT from 16HBE cells and
BECs. For detailed methods of these experiments, please
refer to the Additional file 1.
Statistical analysis
Statistical analysis was performed with the SPSS software
package (SPSS, Chicago, IL, USA). Comparisons of groups
were performed using t-test or ANOVA. Non-normally
distributed data were assessed by Mann–Whitney U test
or the Kruskal-Wallis test, where appropriate. A P value
of < 0.05 was considered to be significant.Results
Expression of M-AAT and Z-AAT by transfected
16HBE cells
Initial experiments were undertaken in the immortalized
BEC line (16HBE), which was engineered to express hu-
man Z and M-AAT. SDS-PAGE and Western blot analysis
of the transfected 16HBE cell line demonstrated that AAT
was only detected in the NP40-insoluble fraction of lysates
from cells transfected with Z-AAT, suggesting that only
the mutant protein forms polymers, and that a fraction of
these are insoluble. In both the NP40-soluble fraction of
the cell lysate and in the culture medium, a higher amount
of AAT was detected for M-expressing 16HBE cells, when
compared to Z-expressing 16HBE cells (Figure 1A).
Polymers of Z-AAT form within transfected 16HBE cells
To further characterize the AAT protein produced by
transfected cells, we used a nondenaturing PAGE protocol
to resolve any conformers of the protein that might be
produced. Western blot analyses using a polyclonal anti-
body that detects all AAT revealed that both in the
medium and the NP40-soluble cell lysate from M-AAT
transfected cells, AAT protein was primarily in the mono-
meric form. This contrasted with the protein that was de-
tected in Z-AAT transfected cells, which showed a high
proportion of polymers in both the cell lysate and the cul-
ture medium (Figure 1B). To further investigate the pro-
duction of AAT polymers, we performed nondenaturing
PAGE and Western blot analysis on the NP40-soluble
fraction of the cell lysate and culture media from trans-
fected 16HBE cells using the ATZ11 antibody. Polymers
were not detected in cells that had been transfected with
M-AAT, which contrasted with the presence of AAT poly-
mers in Z-transfectants (Figures 1C and D).
Inflammation increases the endogenous expression
of M-AAT in 16HBE cells
The effect of an inflammatory stimulus, provided by
Oncostatin M, on endogenous expression of AAT by
16HBE cells was assessed by real-time PCR and ELISA
following exposure to Oncostatin M for 24 hours.
Results from real-time PCR, carried out on total ribo-
nucleic acid (RNA) extracted from cell lysates, demon-
strated that expression of AAT increased 6.5-fold in
Oncostatin M-treated cells, as compared to nontreated
cells (P < 0.05; Figure 2A). ELISA carried out on the cell
culture medium detected a 2.4-fold increase of AAT
protein in Oncostatin M-treated versus nontreated cells
(P < 0.05; Figure 2B).
Bronchial biopsies from Z-AAT homozygous patients
contain polymers
Immunohistochemistry was performed on bronchial bi-
opsies. Staining with the ATZ11 antibody revealed that
Figure 1 Expression of M- or Z-AAT in the 16HBE cell line.
(A) 16HBE cells expressing M- or Z-AAT were assayed for AAT expression
by SDS PAGE and Western blot analysis. 24 hours after transfection,
proteins from 50 μl of cell culture media or from 10 μg or 10 μl of
NP40-soluble and insoluble cell lysates respectively were separated by
SDS-PAGE, transferred to PVDF membranes, and hybridized with
anti-AAT antibody to detect total AAT protein. Purified human serum
AAT (hAAT) was used as positive control. Typical fluorograms from
three independent experiments, which gave superimposable results,
are shown. (B) Nondenaturing PAGE and Western blot analysis using
anti-AAT antibody to detect total AAT in 10 μg of NP40-soluble cell
lysate and 10 μl of cell culture media from 16HBE cells expressing
M- or Z-AAT. The migration of polymeric and monomeric AAT species
is indicated. Typical fluorograms from three independent experiments,
which gave superimposable results, are shown. (C) Nondenaturing PAGE
and Western blot analysis using the antipolymeric Z-AAT antibody ATZ11
in NP40-soluble cell lysate fraction (10 μg) and (D) cell culture media
(50 μl)from 16HBE cells expressing M- or Z-AAT. Typical fluorograms
from three independent experiments, which gave superimposable
results, are shown. Definition of abbreviations: AAT = alpha-1
antitrypsin; h-AAT = human serum AAT; PAGE = polyacrylamide gel
electrophoresis; PVDF = polyvinylidene fluoride; SDS-PAGE = sodium
dodecyl sulphate polyacrylamide gel electrophoresis.
Figure 2 Effects of Oncostatin M on expression of endogenous
AAT in the 16HBE cell line. Nontransfected 16HBE cells were
cultured in the absence (OsM-) or presence (OsM+) of 50 ng/ml
Oncostatin M for 24 hours, and AAT mRNA expression and AAT
protein secretion were analyzed. (A) Mean AAT mRNA expression
levels, normalized for β-actin expression levels (×103), as measured
by real-time PCR analysis from total cellular RNA. (B) AAT protein
levels as measured by ELISA for total AAT in cell culture media.
The fold increase in expression of Oncostatin M-treated versus
untreated cells is indicated. Results are expressed as mean ± SEM
(n = 3–4). *P < 0.05 Student’s t-test. Definition of abbreviations:
AAT = alpha-1 antitrypsin; ELISA = enzyme-linked immunosorbent
assay; mRNA = messenger ribonucleic acid; Real-time PCR =
reverse transcription real-time polymerase chain reaction;
RNA = ribonucleic acid.
Pini et al. Respiratory Research 2014, 15:112 Page 4 of 10
http://respiratory-research.com/content/15/1/112biopsies from M-AAT homozygous patients showed no
evidence of AAT in non-native conformations (Figure 3).
In contrast, positive staining was observed in the sub-
mucosa and epithelial cells (Figure 3) of Z-AAT homozy-
gotes, suggesting the presence of Z-AAT polymers. As
previously reported [26], positive staining was also ob-
served in endothelial vessels. The specificity of immuno-
staining was demonstrated by the absence of a signal in
sections incubated with the antibody isotype control and
by omission of the primary antibody (data not shown).
AAT is normally produced by BECs cultured ex vivo
Secretion of AAT by BECs collected from M- and Z-
AAT homozygous patients was investigated. SDS-PAGE
followed by Western blot analyses with a polyclonal
anti-AAT antibody was performed on the culture media
of ex vivo cultured cells that had been collected by epi-
thelial brushing. Consistent with the results obtained
from transfected 16HBE cells, epithelial cells derived
from Z-AAT patients were able to secrete AAT protein,
but to a lesser degree than cells derived from M-AAT
patients (Figure 4A). The AAT protein present in the
medium for both types of cells was in the form of a sin-
gle band running at the same position as a purified hu-
man AAT control. There was no evidence of complexed
or cleaved AAT in these samples.
Figure 3 Immunohistochemistry of bronchial epithelial biopsy. Endobronchial biopsy sections taken from patients homozygous for M-AAT
or Z-AAT were fixed and stained with the ATZ11 antibody. Evidence of polymers of Z-AAT was confirmed in the epithelial cells and submucosa of
Z-AAT homozygote tissue. Definition of abbreviation: AAT = alpha-1 antitrypsin.
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ELISA was performed on the culture media of BECs
from M- and Z-AAT homozygotes using the ATZ11
antibody. We found a significantly higher signal in the
samples from Z-AAT patients compared with those
from M-AAT patients (P < 0.01; Figure 4B). These re-
sults are consistent with the presence of Z-AAT poly-
mers in culture medium conditioned by Z-AAT BECs,
in agreement with our findings in transfected cultured
cells.A
Figure 4 Detection of AAT in ex-vivo cultured BECs. (A) SDS-PAGE and
10x concentrated culture media from a 72-hour culture of ex vivo BECs from
for Z-AAT. Purified human serum AAT (h-AAT) served as positive control. A
superimposable results, is shown. (B) Cell culture media from a 72-hour cu
seven patients homozygous for Z-AAT were concentrated 10 times, opport
by an ELISA for total AAT, and were analyzed by ELISA using the antipolym
of abbreviations: AAT = alpha-1 antitrypsin; BEC = bronchial epithelial cell; h
ELISA = enzyme-linked immunosorbent assay.Inflammation increases the expression of AAT and the
formation of Z-AAT polymers in BECs cultured ex vivo
To investigate whether AAT expression by patient-
derived BECs was increased by inflammation, cell cul-
tures were supplemented with Oncostatin M. BECs from
homozygous M-AAT or Z-AAT patients were exposed
to Oncostatin M for 24 hours or left untreated, and
cellular levels of AAT messenger RNA (mRNA) were
analyzed by real-time PCR. There was a significant
increase in levels of AAT mRNA in cells exposed toB
Western blot analysis using an antibody to detect total AAT in 20 μl of
five patients homozygous for M-AAT and four patients homozygous
typical fluorogram from three independent experiments, which gave
lture of ex vivo BECs from six patients homozygous for M-AAT and
unely diluted to a final concentration of 10 μg/ml of AAT as assessed
eric AAT antibody ATZ11. . *P = 0.01 Mann–Whitney U test. Definition
-AAT = human serum AAT; PAGE = polyacrylamide gel electrophoresis;
Figure 5 The effect of Oncostatin M on Z-AAT expression in
ex-vivo cultured BECs. (A) Real-time PCR analysis for AAT mRNA in
ex vivo cultured BECs from patients homozygous for M-AAT or Z-AAT.
Cells from four patients homozygous for Z-AAT and five patients
homozygous for M-AAT were incubated in the absence (OsM-) or
presence (OsM+) of Oncostatin M (50 ng/ml) for 24 hours. After
treatment cells from M-AAT and Z-AAT patients were pooled and AAT
mRNA levels were measured. The fold increase in expression of
Oncostatin M-treated versus control cells is indicated. Results are
expressed as mean ± SEM (n = 3–4). *P < 0.05 Student’s t-test. (B) ELISA
for total AAT protein in cell lysates and (C) cell culture media of ex vivo
cultured BECs from four Z-AAT and five M-AAT homozygous patients.
Cells were incubated in the absence (OsM-) or presence (OsM+) of
Oncostatin M (50 ng/ml) for 24 hours and the intracellular AAT
accumulation and secretion were measured for lysates of pooled cells
and 10x concentrated cell culture media, respectively. Results are
expressed as mean ± SEM (n = 3–4). *P < 0.05 ANOVA followed by
Bonferroni t-test, Oncostatin M-treated versus untreated cells; +P < 0.05
ANOVA followed by Bonferroni t-test, M-AAT– versus Z-AAT–expressing
cells. SDS-PAGE and Western blot analysis using an antibody to detect
total AAT was carried out on the cell culture media of ex vivo cultured
BECs. Cells from five patients homozygous for Z-AAT (D) and five
patients homozygous for M-AAT (E) were cultured in the absence
(OsM-) or presence (OsM+) of 50 ng/ml of Oncostatin M. At 24 hours
after treatment cell media were harvested and concentrated 10x.
Typical fluorograms from three independent experiments, which gave
superimposable results, are shown.
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which was detected in both M- and Z-AAT–expressing
cells, at a comparable level (6.7- vs. 6.9-fold increase,
respectively; Figure 5A).
To confirm that AAT mRNA induction by Oncostatin
M treatment of BECs actually leads to an increase in
AAT protein accumulation and secretion, an ELISA
using the antibody for total AAT was carried out on cell
lysates and culture media of cells from M- and Z-AAT
homozygotes. Cells from different patients of each geno-
type were exposed to Oncostatin M for 24 hours or left
untreated. In the lysate of M-AAT–expressing cells, a
significant increase in AAT protein was present in
Oncostatin M-treated cells compared with the untreated
cells (P < 0.05), whereas, in Z-AAT cell lysates, AAT
basal level was undetectable and became measurable
only after Oncostatin M stimulation (Figure 5B). In
culture media from untreated cells, a higher concentration
of AAT was present from M-AAT when compared to
Z-AAT–expressing cells (P < 0.05, Figure 5C). Oncostatin
M treatment significantly increased the amount of AAT
secreted in the media for both cell types (P < 0.05). It is
noteworthy that, irrespective of the total AAT amount,
Oncostatin M treatment induces the same fold increase
of secreted AAT compared to basal levels of the protein
level in the media from both M- and Z-AAT–expressing
cells. The increased amount of AAT secreted in cell
media from BECs treated with Oncostatin M was also
seen when the samples were analyzed by SDS-PAGE
and Western blot using a polyclonal anti-total AAT
antibody (Figures 5D and E), in agreement with our
ELISA results.
To analyse the effect of Oncostatin M treatment on
AAT polymer accumulation and secretion in BECs, we
performed ELISA with the ATZ11 antibody on pooled
samples of patients’ Z-AAT bronchial cells cultured in
the presence of Oncostatin M for 24 hours or left un-
treated. Oncostatin M significantly increased the ATZ11
signal in cell culture medium and within the BECs (P <
0.01), consistent with an increase in Z-AAT polymer ac-
cumulation and secretion during inflammatory condi-
tions (Figure 6).
Discussion
Here we provide, for the first time, strong evidence that
BECs derived from Z-AAT patients are able to accumulate
and secrete Z-AAT in the form of polymers. Moreover, we
show that secretion of Z-AAT is increased in response to
inflammation. Initially, we undertook studies in 16HBE
cells engineered to express M- or Z-AAT to detect the ex-
pression of AAT protein, and to establish the degree to
which Z-AATand M-AAT were expressed, retained, or se-
creted in this in vitro model. The rationale for using this
cell line was based on previous observations of these cells’
Figure 6 Effect of OsM on AAT polymers formation in ex-vivo
cultured BECs. ELISA for polymeric AAT protein, using the ATZ11
antibody, in cell culture media and cell lysates of ex vivo cultured
BECs from Z-AAT homozygous patients. Cells from five patients were
incubated in the absence (OsM-) and presence (OsM+) of Oncostatin
M (50 ng/ml) for 24 hours, and AAT secretion and intracellular accu-
mulation were measured in the 10x concentrated cell medium. Re-
sults are expressed as mean absorbance ± SEM (n = 3–4), measured
at 450 nm. *P = < 0.01 Student’s t-test. Definition of abbreviations:
AAT = alpha-1 antitrypsin; BEC = bronchial epithelial cell; ELISA =
enzyme-linked immunosorbent assay; SEM = standard error of mean.
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human airway epithelial cells [25]. Our results reveal that
Z but not M-AAT is present in the NP40-insoluble cell
fraction of cell lysates, likely due to the formation of Z-
AAT polymers in these cells. This could lead to the forma-
tion of Z-protein globular inclusions within the cells, in a
mechanism analogous to that observed in hepatocytes
[28]. Our analysis also showed that a higher amount of
soluble intracellular AAT is present in M- rather than Z-
AAT–expressing cells. These data, which agree with re-
sults from a previous study performed using Chinese
Hamster Ovary cells [29], may be explained by increased
degradation of the mutant protein and by its sequestration
as aggregates within the insoluble fraction. AAT protein is
efficiently secreted into the cell media by M-AAT–ex-
pressing cells, while only a lower amount of the protein
was found in the cell media from Z-AAT–expressing cells,as previously reported in other cell models of AAT defi-
ciency [29-31].
The results obtained in cell lines were consistent with
our observations from BECs originating from patients
who were homozygous for M- or Z-AAT. We have shown
that BECs from Z-AAT homozygous patients secrete less
AAT than those from M-AAT homozygous patients. Our
data also indicate that these differences do not arise from
differences at the transcriptional level, since a comparable
amount of AAT mRNA was detected in the cells from
both sets of patients. This suggests that, similar to what
we describe in our in vitro cell model, and as widely re-
ported in the literature for different cell types, low levels
of Z-AAT protein in ex vivo BEC cultures can be ascribed
to post-translational events, including intracellular deg-
radation and/or accumulation as intracellular polymers.
Aberrantly polymerized Z-AAT protein is known to
accumulate in the endoplasmic reticulum (ER) of hepa-
tocytes [28]. Accumulation of these polymers within the
ER can induce or predispose to the activation of cellular
stress responses, including the unfolded protein re-
sponse and the ER overload response [29,31,32]. In he-
patocytes, Z-AAT accumulation can lead to apoptosis
whereas, paradoxically, it is associated with cell survival
in BECs [31]. The pathophysiological effect of Z-AAT is
thus manifold: the secretion of functional circulating
AAT is markedly decreased, creating a protease/antipro-
tease imbalance with neutrophil elastase; accumulation
of Z-AAT polymers can have a deleterious effect on the
ER, leading to the activation of ER stress pathways; and,
depending on the producer cell, accumulation of Z-AAT
can mediate either cell survival or apoptosis.
The combined processes of intracellular degradation
and retention of Z-AAT contribute to the pathogenesis
of AAT deficiency, however, it has been proposed that
the pro-inflammatory effect of secreted Z-AAT polymers
could exacerbate the tissue damage that occurs in em-
physema [33]. It is thus important to investigate the
presence of Z-AAT polymers produced locally by lung
epithelial cells, in addition to circulating polymers that
can arise from the liver. This was assessed with a
conformation-specific monoclonal antibody, the ATZ11
antibody, which has been used in the past to detect poly-
mers of Z-AAT [19,27].
Here we demonstrate the presence of intracellular and se-
creted Z-AAT polymer in Z-AAT–expressing 16HBE cells.
The small proportion of M polymer that was also detected
in cell lysates was unexpected and it is likely to be a result
of the high expression of plasmid-derived M-AAT. Most
importantly, ATZ11-positive Z-AAT was detected in bron-
chial biopsies from Z-AAT homozygous patients and in the
cell media from their ex vivo BECs. This suggests a role for
bronchial epithelium in Z-AAT polymer deposition in
bronchial airways. It should be noted that, although we
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in culture media from Z-AAT expressing 16HBE cells, de-
finitive demonstration of the presence of Z-AAT polymers
in culture media from patient’s cells was obtained only by
using ELISA with ATZ11 antibodies, likely because the
higher sensitivity of ELISA in comparison to native PAGE/
WB technique. Results from ex vivo cells also suggest that
the amount of polymeric Z-AAT that is produced by BECs
could differ between individuals, as demonstrated by the
variability that was observed in total Z-AAT secretion into
culture media by patients’ cells. With this result in mind, it
can be speculated that differing amounts of Z-AAT poly-
mers could correlate with the degree of lung disease that is
seen in AAT-deficient patients. Our results differ from the
ones of Van’t Wout et co-authors [34] who did not find any
evidence of Z-AAT polymers in cultured BEC from Z-AAT
homozygous patients. This meaningful difference may be
explained by an increased sensitivity of our experimental
approach to detect Z-AAT polymers and by differences be-
tween the two experimental models. Indeed, differently
from Van’t Wout and co-authors, we concentrated the
sample before the analysis and used the anti-polymeric
AAT antibodies ATZ11 which, although less specific, is
more sensitive for Z-AAT polymers than the antibody they
used [35]. We are also confident that signal we measured is
due to the presence of polymers since we could not detect
SDS-stable protease-AAT complex or cleaved AAT bands
in our Western blots of culture medium from Z-AAT
BECs, thus excluding the most relevant sources of potential
false-positive ATZ11 signals. Moreover, in our experimental
condition, BECs from both M-AAT and Z-AAT patients’
cells seem to produce higher amounts of AAT since, differ-
ently from what reported by Van’t Wout and co-authors,
AAT production (both in cell lysate and culture media) is
detectable already in basal condition thus allowing us to de-
tect low but significant levels of polymeric Z-AAT.
The effect of inflammation on the expression of Z-
AAT was also investigated, to ascertain whether it in-
creases the expression of the mutant protein, as in the
case of lung-derived epithelial cell expression of wild-
type AAT [3]. Results from real-time PCR, denaturing
SDS-PAGE, and ELISA showed that Oncostatin M treat-
ment of patients’ BECs increases the expression of Z-
AAT. Moreover, we demonstrate that the inflammatory
stimulus increases the presence of Z-AAT polymers in
the culture medium. Due to the pro-inflammatory and
chemotactic function of AAT polymers [19], our findings
may help to understand why the clinical outcome is so
much worse for Z-AAT patients exposed to inflamma-
tory agents such as cigarette smoke. Cigarette smoke
may increase AAT production by BECs, leading to an in-
creased deposition of polymeric AAT in Z-AAT individ-
uals who smoke.The accumulation of AAT polymers in BECs exposed to
an inflammatory stimulus (Oncostatin M) may help us to
understand why we did not detect polymeric AAT in cell
lysates of primary cell cultures of untreated ex vivo bron-
chial cells, contrasting with observations from bronchial
biopsies and transfected 16HBE cells. Tissue culture of
ex vivo cells requires several proliferative cycles before a
stable culture has been established, which could dilute
pre-existing intracellular aggregates; moreover, cells in
culture have a limited lifespan, which may explain why
polymer accumulation might not be detectable at steady
state conditions. Our results show that, upon treatment
with Oncostatin M, the higher level of Z-AAT expression
leads to increased deposition of intracellular Z-AAT
polymers.
Conclusion
In conclusion, our study shows that BECs from Z-AAT
patients are able to express, accumulate, and secrete Z-
AAT protein and its polymers, and that this process is
increased by inflammatory stimuli. This suggests that
these cells may be involved in the pathogenesis of lung
emphysema and in BEC dysfunction. These findings
strengthen the rationale for the development of new
therapeutic approaches, such as treatments to prevent
polymer formation, for managing AAT-deficiency–re-
lated diseases [36].
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